Therapy options for advanced-stage HL. The flowchart shows therapy options for patients with advanced-stage HL based on IPS risk and response on interim PET scan. Percentages of patients with a positive or negative interim PET scan and PFS percentages are based on the RATHL, the AHL 2011 LYSA, and the ECHELON-1 trials, assuming that AVD is equivalent to ABVD for interim PET-negative patients. *mPFS values are for patients who had a negative or positive interim PET scan after 2 cycles of BV-AVD. Adapted with permission from Lim and Johnson.⁴⁵